Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
about
Biomarkers for the effects of benzodiazepines in healthy volunteersEntry-into-humans study with ACT-462206, a novel dual orexin receptor antagonist, comparing its pharmacodynamics with almorexantThe effects of ketamine and risperidone on eye movement control in healthy volunteers.Functional biomarkers for the acute effects of alcohol on the central nervous system in healthy volunteers.Preclinical assessment of CNS drug action using eye movements in mice.Can Functional Magnetic Resonance Imaging Improve Success Rates in CNS Drug Discovery?Central nervous system effects of the interaction between risperidone (single dose) and the 5-HT6 antagonist SB742457 (repeated doses) in healthy men.Pharmacological treatment effects on eye movement controlBiomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects.A review of acute effects of 3,4-methylenedioxymethamphetamine in healthy volunteers.Biomarkers for the effects of cannabis and THC in healthy volunteers.Central nervous system effects of alcohol at a pseudo-steady-state concentration using alcohol clamping in healthy volunteers.Schizophrenia as a disorder of too little dopamine: implications for symptoms and treatment.Use of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.Model-based approaches to increase efficiency of drug development in schizophrenia: a can't miss opportunity.Pharmacokinetics and central nervous system effects of the novel dual NK1 /NK3 receptor antagonist GSK1144814 in alcohol-intoxicated volunteers.Gallbladder volume as a biomarker for the motilin effect in healthy volunteers and patients with functional dyspepsia.Amygdala Lesions Reduce Anxiety-like Behavior in a Human Benzodiazepine-Sensitive Approach-Avoidance Conflict Test.The effects of the glycine reuptake inhibitor R213129 on the central nervous system and on scopolamine-induced impairments in psychomotor and cognitive function in healthy subjects.Central nervous system effects of haloperidol on THC in healthy male volunteers.Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment.Single oral dose safety, tolerability, and pharmacokinetics of PNU-96391 in healthy volunteers.Psychomotor and cognitive effects of a single oral dose of talnetant (SB223412) in healthy volunteers compared with placebo or haloperidol.Optimizing the glutamatergic challenge model for psychosis, using S+ -ketamine to induce psychomimetic symptoms in healthy volunteers.The uses of biomarkers in drug development.Pharmacokinetics and central nervous system effects of the novel dopamine D2 receptor antagonist JNJ-37822681.Does olanzapine inhibit the psychomimetic effects of Δ⁹-tetrahydrocannabinol?Pharmacokinetics and central nervous system effects of the novel dopamine D3 receptor antagonist GSK598809 and intravenous alcohol infusion at pseudo-steady state.Pathological dissociation and neuropsychological functioning in borderline personality disorder.Selective deficit in executive functioning among patients with borderline personality disorder.Effects of risperidone, amisulpride and nicotine on eye movement control and their modulation by schizotypy
P2860
Q24679523-3C5E6969-35D4-4249-BB74-4C062484E730Q28237266-3E1EC297-455F-40C4-AFC5-9F25D0EDD93EQ30437913-8B060288-987D-4F43-B176-8D2F805FDDD3Q30469906-9A97012D-AC92-4C5E-9F97-C902F70D4120Q30503853-0645DFBC-3D66-47F3-B09B-CF689C32F247Q33963735-FBA801A5-6313-4F4B-86F2-73931BBEFF1FQ34996934-94C9F391-51EF-4848-AC8A-DB8F1AC94FFCQ35173870-A3B8977F-2E91-4B8B-9BE4-95EA780D70C3Q36103113-D6239FBD-7860-4861-9083-ECA1E8922ABDQ36410788-F62630BA-86DA-4056-9F65-0D8AF12B6D8CQ37156258-C24D8B88-FA2D-443E-9EDA-3E57BCD2A506Q37427922-7A85034E-524F-48D1-8AE2-58783DF3252AQ37862242-B6A070CE-BC95-435D-BC44-FFF81FFC345EQ38170140-DBCB1480-8DF7-46A7-BFE0-3347D758DDD9Q39959170-6B35F567-A28C-4425-BE6A-F6C7C5B3D84BQ40086970-F9DF64EA-3BF7-47D6-9710-40C2A009CA3CQ40522309-5D97C5C3-6361-40F3-879A-26BB8B248FECQ41634117-BC8B3B39-7E3D-40F2-9C3A-28D0F29E3E50Q43168345-869314F5-D183-483B-B8A8-D4DF2C49C5B6Q43168358-B96033F8-0D27-45C6-B17A-F95F5B91E994Q44263541-69BC67BD-EDC8-4A57-9AEF-DAAB8D36CD42Q44770194-E2092379-2E3E-4933-8BEC-2DE289C32578Q46404900-5C563BA6-3A5C-477E-AAB3-79228156B845Q47746221-1C6925BE-6771-428E-80C2-13C28B08988DQ48411049-AB625614-C883-4EE3-98A2-DDC677FE4B3EQ48918400-59A951F6-6C0E-4007-A24F-AADA7615185CQ49217905-32F0A87B-7DEF-4FE6-89B3-8B2B5B49CC16Q50666702-FBC8C026-E6A8-44EB-89C5-A4C930AC51A2Q51873561-6921B926-A7A1-43AA-983A-FD6AD2B125B0Q51958420-93410379-9584-4916-9DB2-9E1C139578E7Q57978272-BA021107-0421-4818-A6E1-8C2CC5C22F87
P2860
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
description
2001 nî lūn-bûn
@nan
2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@ast
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@en
type
label
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@ast
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@en
prefLabel
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@ast
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@en
P2093
P2860
P1476
Biomarkers for the effects of antipsychotic drugs in healthy volunteers.
@en
P2093
J M van Gerven
J van der Post
M S Pieters
S J de Visser
P2860
P304
P356
10.1111/J.1365-2125.2001.01308.X
P407
P577
2001-02-01T00:00:00Z